Picture of BioLine RX logo

BLRX BioLine RX Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapMomentum Trap

Annual cashflow statement for BioLine RX, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-23-25.4-30-27.1-25
Depreciation
Non-Cash Items-0.068-2.487.173.32-3.18
Unusual Items
Other Non-Cash Items
Changes in Working Capital-1.714.32-1.29-0.541.24
Change in Accounts Receivable
Change in Payable / Accrued Expenses
Cash from Operating Activities-24.2-22.7-23.2-23.6-26.2
Capital Expenditures-10.2-0.0730-0.097-0.316
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items19.85.3316.7-38.14.32
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities9.555.2616.7-38.24.01
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities13.119.217.957.720.4
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-1.711.8911.5-3.84-2.4